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We found previously that acute phase protein orosomucoid reacts to fatigue and
activates C-C chemokine receptor type 5 to increase muscle glycogen storage and
enhance muscle endurance (Lei et al., 2016). To explore the underlying molecular
mechanisms, we investigated the role of AMP-activated protein kinase, a critical fuel
sensor in skeletal muscle, in C-C chemokine receptor type 5-mediated orosomucoid
action. It was found orosomucoid increased skeletal muscle AMP-activated protein
kinase activation in a time- and dose- dependent manner, which was largely prevented by
pharmacological blocking or knockout of C-C chemokine receptor type 5. Administration
of orosomucoid also significantly increased the de-phosphorylation and activity of muscle
glycogen synthase, the rate-limiting enzyme for glycogen synthesis. The effect was
largely absent in mice deficient in C-C chemokine receptor type 5−/− or AMP-activated
protein kinase α2−/−, the predominant isoform in skeletal muscle. Moreover, deletion
of AMP-activated protein kinase α2 abolished the effect of orosomucoid on fatigue
and muscle glycogen. These findings indicate that orosomucoid may promote glycogen
storage and enhance muscle function through C-C chemokine receptor type 5-mdiated
activation of AMP-activated protein kinase, which in turn activates glycogen synthase
and increases muscle glycogen.
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INTRODUCTION
Orosomucoid (ORM) is an acute phase protein, with very low pI of 2.8–3.8 and a very high
carbohydrate content of 45%. It is predominantly synthesized in the liver and many extra-
hepatic tissues have also been reported to produce ORM under physiological and pathological
conditions. Many biological activities of ORM have been identified including acting as a disease
marker, modulating immunity, and regulating energy homeostasis. Its related receptor has been
preliminarily explored in macrophages, neutrophils, and hypothalamus neurons, involving the
membrane receptor CCR5, Siglect-5, and leptin receptor (LepR), respectively (Luo et al., 2015; Sun
et al., 2016). It was found that ORM induces rises in cytosolic Ca2+ in neutrophil granulocytes via
Siglec-5 tomodulate leukocyte functions during an inflammatory process (Gunnarsson et al., 2007).
Besides, the ORM is able to bind directly to LepR and activate the receptor-mediated JAK2–STAT3
signaling in hypothalamus tissue and GT1-7 cells to regulate food intake and energy homeostasis
in response to nutrition status (Sun et al., 2016).
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In our previous study, we found that the expression of ORM
is markedly increased in response to various forms of fatigue,
such as sleep deprivation, forced swimming, and treadmill
running. Interestingly, ORM is able to act on cell membrane
receptor CCR5 to increase muscle glycogen and enhance muscle
endurance, representing a positive feedback mechanism to resist
fatigue and maintain homeostasis (Yi et al., 2014; Lei et al., 2016).
Noteworthily, the anti-fatigue action of ORM is completely
abolished by CCR5 antagonist or knockout, indicating that CCR5
is the major mediator of the effect. However, the underlying
signal pathway through which ORM-activated CCR5 promotes
the glycogen storage remained unknown.
AMP-activated protein kinase (AMPK), a heterotrimeric
complex composed of one catalytic (α) subunit and two
regulatory subunits (β and γ) (Kahn et al., 2005; Dolinsky et al.,
2015), is reported to be a key sensor of fuel and energy status in
skeletal muscle, and is important for glucose uptake and glycogen
storage in the myocytes (Hardie and Sakamoto, 2006; Hunter
et al., 2011). Recent evidence showed that muscle AMPK played
an important role in exercise. AMPKα2 is the predominant
isoform contributing to AMPK activity in skeletal muscle. Mice
specifically expressing an inactive form of AMPKα2 in skeletal
muscle displayed exercise intolerance (Fujii et al., 2007), and
mice with defective muscle AMPK, named lazy mice, showed a
decrease in voluntary activity (Mu et al., 2001, 2003). Moreover,
whole-body depletion of AMPKα2 was associated with a defect in
glycogen synthesis (Andreelli et al., 2003), and acute or chronic
activation of AMPK could increase the glycogen storage in
skeletal muscle (Ojuka et al., 2000; Vitzel et al., 2001), suggesting a
possible causal relationship between AMPK, glycogen synthesis,
and exercise tolerance.
C-C chemokine receptor type 5 (CCR5) belongs to the
superfamily of G-protein-coupled receptors (Lee et al., 2014),
which contain seven transmembrane helices and transmit signals
from extracellular signals to intracellular pathways through
heterotrimeric G-proteins (de Munnik et al., 2015; Lohse, 2015).
CCR5 is involved in the regulation of inflammation and immune
response and also functions as a coreceptor for HIV to enter into
cells. It is worth noting that CCR5 engagement increases glucose
uptake and activates AMPK to accumulate ATP and meet the
energy demands of chemotaxis in activated T cells (Chan et al,
2012). It was also found that AMPK mediates CCR5-activating
ckemokine-induced cell migration in human chondrosarcoma
(Hsu et al., 2013). Therefore, we ask whether AMPK is critical in
the signal pathway from the ORM/CCR5 activation to glycogen
synthesis in the skeletal muscles and mediates the anti-fatigue
action of ORM.
MATERIALS AND METHODS
Reagents
ORM (Cat. No. G9885) was purchased from Sigma (St. Louis,
MO). CCR5 antagonist Maraviroc was generously provided by
Professor Xin Xie (Shanghai Institute of Materia Medica, CAS).
Antibodies specific to AMPK (Cat. No. 2603), p-AMPK (at T172,
Cat. No. 4188), glycogen synthase (GS, Cat. No. 3893), p-GS (Cat.
No. 3891), and GAPDH (Cat. No. 2118) were obtained from Cell
Signaling (Danvers, MA).
Animals
C57BL/6 mice (18–22 g) were purchased from Sino-British
SIPPR/BK Laboratory Animals (Shanghai, China). The CCR5-
deficient mice (B6.129P2-Ccr5tm1Kuz/J, Stock Number: 005427)
were obtained from Jackson Laboratory (Bar Harbor, MA).
AMPKα2 knockout mice were generated by S. Vaulont as
described previously (Viollet et al., 2003). Mice were 6–8 weeks of
age at the start of the experiments. All animals were maintained
at 22◦C on a 12-h light/dark cycle with free access to water and
a standard rodent diet. All animal experiments were undertaken
in accordance with the National Institute of Health’s “Guide for
the Care and Use of Laboratory Animals,” with the approval of
the Scientific Investigation Board of the Second Military Medical
University.
Cell Culture
C2C12 cells (mouse muscle; myoblast; Cat. No. GNM26)
were obtained from Shanghai Institutes for Biological Sciences,
Chinese Academy of Sciences and cultured in DMEM high
glucose supplemented with 10% fetal calf serum at 37◦C and 5%
CO2. In a dose-effect experiment, C2C12 cells were exposed to
ORM at the doses of 0, 0.1, 1, or 10µg/ml for 2 h (Sörensson et al.,
2000), then cells were harvested to detect the protein expression
of p-AMPK and AMPK.
Weight-Loaded Forced Swimming
Mice were placed individually in a cylindrical glass tank (46 cm
tall, 20 cm in diameter) of water at 21–23◦C. A load consisting
of a steel ring weighing 8% of each body weight was attached to
the proximal end of the tail. The swimming time was measured
from the time the mouse began swimming to the time it could
not return to the surface of the water 10 s after sinking (Lei et al.,
2016). This experiment was performed double-blindedly.
Fatigue Induction in Isolated Muscle
Muscle fibers group into two major categories: slow twitch
type I fibers with high oxidative capacity adapted to endurance
exercise, fast twitch type II fibers with low oxidative capacity
adapted to sprint (Vogel et al., 2015). Due to the role of ORM
in enhancing muscle endurance, slow twitch soleus muscle was
adopted in the present study to explore the mechanism of ORM.
Muscle fatigue was induced as previously reported (Lenman et al.,
1989). Briefly, mice were sacrificed and soleus muscles were
quickly isolated. One end of muscle was fixed, and the other was
linked to the sensor of a biotic signal collection and processing
system (MedLab-U/4CS, MeiYi, Nanjing, China). The muscle
contraction was electrically evoked by trains of stimuli at 10 V
lasting 5ms and delivered each second for consecutive 3min. The
ratio of tension at 1, 2, or 3min to the initial tension (average of
the first five contractions) was expressed as the fatigue index.
Immunoblotting
Immunoblotting analyses were performed using Odyssey
Infrared Fluorescent Imaging system. Samples were lysed
with M-PER protein extraction reagent (Pierce, Rockford,
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IL, Cat. No. 78501) supplemented with protease inhibitor
mixture (CalBiochem, San Diego, Cat. No. 539137). Protein
concentration was estimated using Bradford reagent and
bovine serum albumin as standard. Proteins were separated
through SDS-PAGE and transferred onto PVDF membranes.
The membranes were then incubated in primary antibodies
prepared in TBST solutions (20mM Tris-HCl, 137mM NaCl,
0.1% Tween-20). Detection was performed using appropriate
secondary antibodies conjugated with infrared dyes 680 and 800.
Equal loading of the samples was confirmed by re-probing the
blots for GAPDH.
Glycogen Detection
The glycogen content frommouse soleus muscle was determined
using a glycogen assay kit (Biovision, USA, Cat. No. K646). In
brief, 10mg tissue was homogenized with 200 µl dH2O on ice
and boiled for 10min to inactivate enzymes. The boiled sample
was spun at 18,000× g for 10min to collect the supernatant.
25 µl supernatant was added to a 96-well plate, and the volume
was adjusted to 50µl each well with hydrolysis buffer. 2µl
hydrolysis enzyme mix was added to each well and the mixture
was incubated for 30min at room temperature. Then 50µl
reaction mix was added and the mixture was incubated for
another 30min at room temperature. Absorbance at OD 570 nm
was then measured. Glycogen standard curve was concurrently
prepared.
Measurements of Glycogen Synthase
Activity
Professor Yan Chen (Institute for Nutritional Sciences, Chinese
Academy of Sciences) helped to detect the activity of glycogen
synthase. Briefly, mouse soleus muscle extracts were prepared
by homogenizing 90–100mg powdered muscles on ice in
400 µl of homogenization buffer (50mM Tris-HCl pH 7.8),
100mMNaF, 10mM EDTA, 2mM EGTA, and protease inhibitor
cocktail [Sigma-Aldrich, St. Louis, MO, Cat. No. P8340]).
The homogenates were centrifuged for 5min at 3000 rpm,
and the supernatants were retained to analyze as previously
described (Zhang et al., 2014). Briefly, the supernatants were
measured and adjusted to a concentration of 10mg/ml by
adding homogenization buffer. Muscle extracts (3 ul) were
added to reaction cocktail I (27 ul) containing 25mM Tris-HCl
(pH 7.4), 100mM KCl, 5mM MgCl2, 0.5% Glycogen (Sigma-
Aldrich, St. Louis, MO, Cat. No. G8876), 10mM glucose-6-
phosphate (G-6P), and incubated with or without 5mM 5′-
urdiphosphate-glucose (UDPG, Sigma-Aldrich, St. Louis, MO,
Cat. No. U4625) at 37◦C for 30min. Then the reaction was
terminated at 100◦C for 3min. After centrifugation for 5min
at 10,000 rpm, supernatants (20 ul) were mixed with reaction
cocktail II (10 ul) containing 6mM HEPES (pH 7.4), 100mM
KCl, 5mM MgCl2, 2mM PEP (Sigma-Aldrich, St. Louis, MO,
Cat. No. 860077), 0.4mM NADH (Roche Applied Science,
Penzberg, Germany, Cat. No. 10107735001), 4 units pyruvate
kinase/ml (Sigma-Aldrich, St. Louis, Cat. No. P1506) and 2 units
lactate dehydroxylase (LDH)/ml (Sigma-Aldrich, St. Louis, MO,
Cat. No. L3916). Reaction product was immediately detected by
spectrophotometry at 340 nm, using a microtiter plate reader
(Tecan). Then GS activity was calculated as followed: U/L
= 1A/min∗(V∗106)/(ε∗v∗L). 1A: variation of the absorbance;
V: volume of the reaction system (ml); ε: Molar extinction
coefficient (cm.mol); v: sample amount (ml); L: the light path
length of colorimetric cuvette (cm).
Statistical Analysis
Data were expressed as mean ± s.d. Statistical analyses were
performed using Student’s t-test when comparing two samples
with equal variance (Figure 1) or one-way ANOVA with
Dunnett’s post-hoc test for the comparison of multiple treatments
to controls (Figure 2). In Figures 3–6, statistical evaluation
was performed by two-way ANOVA. When ANOVA revealed
significant differences, a post hoc test was used to correct for
multiple comparisons (Turkey’s test). Differences between groups
were considered statistically significant at P < 0.05.
RESULTS
Mice Deficient in AMPKα2 Have Reduced
Muscle Endurance and Glycogen Synthesis
We first testified whether AMPKα2 is involved in the regulation
of muscle endurance and glycogen storage. Isolated mouse soleus
FIGURE 1 | Mice deficient in AMPKα2 have reduced muscle endurance and glycogen synthesis. (A) Representative records of electrically evoked
contractions of soleus muscle isolated from AMPKα2+/+ (n = 6) and AMPKα2−/− mice (n = 6) for consecutive 3min. Data are expressed as the mean ± s.d.
*P < 0.05 by Student’s t-test. (B) Soleus muscle glycogen contents in AMPKα2+/+ (n = 6) and AMPKα2−/− mice (n = 6). Data are expressed as the mean ± s.d.
**P < 0.01 by Student’s t-test.
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FIGURE 2 | ORM can induce the activation of AMPK in skeletal muscles. (A) Representative western blotting of p-AMPK and total AMPK and quantification of
the result in C2C12 cells treated with indicated doses of ORM for 2 h (n = 3 per dose). (B) Representative western blotting of p-AMPK and total AMPK and
quantification of the result at indicated time in soleus muscle tissues of mice treated with 200mg/kg of ORM via tail vein injection (n = 6 per time point). All data are
expressed as the mean ± s.d.*P < 0.05, **P < 0.01 by one-way ANOVA with Dunnett’s post-hoc test.
muscle was utilized to electronically induce fatigue in vitro. As
shown in Figure 1A, AMPKα2 knockout significantly decreased
the fatigue index at 1, 2, and 3min of the stimulation, suggesting
that AMPK may directly enhance muscle endurance. Consistent
with previous reports (Andreelli et al., 2003), AMPKα2 knockout
mice have significantly decreased muscle glycogen content when
compared to that in their wild littermates (Figure 1B). We
suspected that AMPK may mediate the effect of ORM/CCR5 in
enhancing muscle endurance and glycogen synthesis.
ORM Can Induce the Activation of AMPK in
Skeletal Muscles
We further detected whether ORM can induce the activation
of AMPK in the skeletal muscles. It has been shown that
phosphorylation at T172 significantly increases AMPK activity
and may also be used as a readout for its activation (Hawley
et al., 1996). We found in myoblast cell C2C12, 0.1–10 µg/ml
of ORM treatment for 2 h resulted in AMPK phosphorylation at
T172 in a dose-dependent manner (Figure 2A). In mice injected
with 200mg/kg of ORM via tail-vein, serum ORM concentration
peaked at 15min post-injection then gradually declined (Lei
et al., 2016, see Figure S5), and soleus muscle AMPK was
phosphorylated at 15min and the amount of phosphorylated
AMPK peaked at 120min post-injection (Figure 2B).
ORM-Induced AMPK Activation Is
Dependent of CCR5 in Skeletal Muscles
Since ORM could induce AMPK activation and the anti-fatigue
effect of ORM was mediated through binding to CCR5 in the
skeletal muscle (Lei et al., 2016), we want to figure out whether
CCR5 is involved in the ORM-induced activation of AMPK. As
shown in Figures 3A,B, tail-vein injection of 200mg/kg of ORM
for 2 h induced the phosphorylation of soleus muscle AMPK,
which was inhibited by administration of CCR5 antagonist
Maraviroc (200mg/kg, via gastric gavage, for 3 days) and was
largely absent in CCR5−/−mice, suggesting that activation of
AMPK is a downstream event of CCR5 activation.
It is worth noting that, we previously found that the binding
of ORM to C2C12 skeletal muscle cells is incompletely inhibited
by the CCR5 antibody and antagonist, indicating ORMmay bind
to other cell surface proteins (Lei et al., 2016). We subsequently
found ORM was able to bind directly to LepR in hypothalamus
to regulate energy homeostasis. More interestingly, ORM also
bound to LepR in C2C12 cells and induced LepR-mediated JAK2-
STAT3 activation (Sun et al., 2016, see Figures S7, S8). We
therefore further explored whether LepR is also involved in the
AMPK activation triggered by ORM in skeletal muscle. As shown
in Figure 3C, ORM still remains similar stimulatory effect in
AMPK activation in the soleus muscle from LepR deficient db/db
mice when compared to that in C57BL/6 mice, indicating ORM-
triggered AMPK phosphorylation is not dependent of LepR.
CCR5 Mediates the Role of ORM in
Promoting the Expression and Activity of
Glycogen Synthase in Skeletal Muscles
Our previous results revealed that ORM engaged CCR5 to
increase the glycogen content in skeletal muscle. Glycogen
synthase (GS) is the rate-limiting enzyme of glycogen synthesis,
and de-phosphorylated GS is the active form responsible for
the synthesis of glycogen (Ferrer et al., 2003). We wondered
whether GS was involved in this CCR5-activated glycogen
accumulation. Western blot analysis revealed that 200mg/kg
of ORM significantly increased the expression of total GS
and decreased the ratio of phosphorylated GS in total GS in
the soleus muscles in wild-type mice, but not in CCR5−/−
mice (Figure 4A). Meanwhile, GS activity is markedly increased
in soleus muscles from mice treated with ORM, which is
inhibited in CCR5−/− mice, suggesting that ORM promoted
the GS activity through CCR5 (Figure 4B). Interestingly, the
upregulation of glycogen synthase protein happened at 30min
post ORM-injection, indicating that it may be regulated as an
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FIGURE 3 | ORM-induced AMPK activation is dependent of CCR5 in skeletal muscles. (A) Representative western blotting of p-AMPK and total AMPK and
quantification of the result in soleus muscle tissues of mice 30min after tail-vein injection with vehicle, 200mg/kg ORM, 200mg/kg ORM in absence or presence of
200mg/kg Maraviroc (MVC, gastric gavage for consecutive 3 days). n = 6 per group. (B) Representative western blotting of p-AMPK and total AMPK and
quantification of the result in soleus muscle tissues of CCR5+/+ or CCR5−/− mice 30min after tail-injection with vehicle or 200mg/kg ORM. n = 6 per group. (C)
Representative western blotting of p-AMPK and total AMPK and quantification of the result in soleus muscle tissues of C57BL/6 or db/db mice 30min after
tail-injection with vehicle or 200m˙g/kg ORM. n = 6 per group. All data are expressed as the mean ± s.d. NS, non-significant, **P < 0.01 by two-way ANOVA with
Turkey’s post-hoc test.
FIGURE 4 | CCR5 Mediates the Role of ORM in Promoting the
Expression and Activity of Glycogen Synthase in Skeletal Muscles. (A)
Representative western blotting of soleus muscle glycogen synthase and
phosphorylated glycogen synthase and quantification of the results 30min
after the treatment with vehicle or 200mg/kg ORM (tail vein injection) in
CCR5+/+ and CCR5−/− mice. n = 6 per group. (B) The activity of glycogen
synthase in soleus muscle of mice treated as mentioned in (A). n = 6 per
group. GS: glycogen synthase; p-GS: phosphorylated glycogen synthase. All
data are expressed as the mean ± s.d. NS, non-significant, **P < 0.01 by
two-way ANOVA with Turkey’s post-hoc test.
immediate early gene at transcriptional level or affected by
protein degradation system at post-transcriptional level, which is
worthy of being deeply explored.
AMPK Mediates the Role of ORM in
Promoting the Expression and Activity of
Glycogen Synthase in Skeletal Muscles
We further wondered whether ORM/CCR5-activated-AMPK
was also involved in the GS regulation. As shown in Figure 5,
vein injection with 200mg/kg of ORM for 30min resulted in
the significant increase in the expression of total GS (Figure 5A)
and its activity (Figure 5B) in skeletal muscle in AMPKα2+/+
mice, but absent in AMPKα2−/− mice, indicating this effect was
mediated by AMPK pathway.
AMPK Mediates the Anti-Fatigue and
Glycogen-Storage Action of ORM
We have previously reported that administration of purified
ORM to the normal mice could significantly extend their
swimming time and increase their muscle glycogen storage via
CCR5, in which deletion of CCR5 abolished the effect of ORM
on fatigue and muscle glycogen (Lei et al., 2016). Since AMPK
is the downstream event of ORM/CCR5 activation, we want to
make sure that whether AMPK is involved in the regulation
of swimming endurance and glycogen storage of ORM. Here
we found that in AMPKα2 deficient mice, the ability of ORM
to increase the swimming time was completely diminished
and it also failed to increase muscle glycogen in these mice
(Figures 6A,B). These results indicated that the CCR5-mediated
AMPK activation is required for ORM to enhance muscle
performance and glycogen storage.
DISCUSSION
Our previous study demonstrated that ORM could act on
CCR5 to exert its anti-fatigue effect by increasing glycogen
synthesis in skeletal muscle. However, the downstream pathway
mediating this effect remained unclear. In this study, we
presented the first evidence that ORM engaged CCR5 can activate
AMPK in skeletal muscle, which led to the activation of GS
and subsequent glycogen storage and endurance enhancement.
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FIGURE 5 | AMPK Mediates the Role of ORM in Promoting the
Expression and Activity of Glycogen Synthase in Skeletal Muscles. (A)
Representative western blotting of soleus muscle glycogen synthase and
phosphorylated glycogen synthase and quantification of the results 30min
after the treatment with vehicle or 200mg/kg ORM (tail vein injection) in
AMPKα2 +/+ or AMPKα2−/− mice. n = 6 per group. (B) The activity of
glycogen synthase in soleus muscle of mice treated as mentioned in (A). n = 6
per group. GS: glycogen synthase; p-GS: phosphorylated glycogen synthase.
All data are expressed as the mean ± s.d. NS, non-significant, *P < 0.05, **P
< 0.01 by two-way ANOVA with Turkey’s post-hoc test.
FIGURE 6 | AMPK mediates the anti-fatigue and glycogen-storage
action of ORM. (A) Swimming time of AMPKα2+/+ or AMPKα2−/− mice
30min after tail-vein injection with vehicle (Ctr) or 200mg/kg ORM. n = 6 per
group. (B) Muscle glycogen content 30min after tail-vein injection with vehicle
or 200mg/kg ORM in AMPKα2+/+ or AMPKα2−/− mice. n = 6 per group. All
data are expressed as the mean ± s.d. NS, non-significant, *P < 0.05, **P <
0.01 by two-way ANOVA with Turkey’s post-hoc test.
Therefore, modulation of the ORM1/CCR5/AMPK system could
be a novel strategy for therapeutic intervention of fatigue.
Leptin was also reported to activate AMPK via leptin receptor
in soleus muscle (Minokoshi et al., 2002). We found ORM could
bind to LepR in C2C12 cells and activate LepR-mediated JAK2-
STAT3 pathway (Sun et al., 2016), but its effect of triggering
AMPK phosphorylation in soleus muscle is independent of LepR
as shown in Figure 3C. Interestingly, the binding of ORM to
the hypothalamic GT1-7 cells was not competitively blocked by
leptin, which is possibly due to their different binding site in LepR
according to structural studies (Sun et al., 2016). We speculate
this difference in the LepR binding site may be also responsible
for their difference in the LepR-mediated AMPK activation.
We found here that ORM-mediated CCR5 activation can
trigger AMPK phosphorylation at threonine 172 (T172). AMPK
is activated through allosteric effect when intracellular levels
of AMP and ADP are increased, leading to increased ATP
production and switching off biosynthesis pathways (Hardie and
Sakamoto, 2006). Activation of AMPK requires phosphorylation
of T172 within the T loop segment of the catalytic α subunit
(Hawley et al., 1996) by one or more AMPK kinases (AMPKKs).
Recent studies have shown that LKB1 (Koh et al., 2008)
and Ca2+/calmodulin kinase kinase [CaMKK, which could be
activated by Ca2+ influx Woods et al., 2005; Shen et al., 2007]
can serve as upstream kinases for AMPK. Given that muscle-
specific LKB1 knockout mice (Sakamoto et al., 2005) show
ablated AMPKα2 activity in skeletal muscle, LKB1 appears to be a
major AMPK kinase in skeletal muscle. Whether CCR5-triggered
AMPK phosphorylation was mediated by AMP/ATP (LKB1-
dependent) or Ca2+-mediated CaMKK pathway in skeletal
muscle should be further explored.
It has been reported that likely through the PLC-γ and
Ca2+ pathway, CCR5 engagement activates AMPK to stimulate
glycolysis (Chan et al, 2012; Lin et al., 2014). However, our
present data suggested that CCR5-triggered AMPK activation
was able to promote glycogen synthesis, not glycogenolysis,
as a means to store energy in skeletal muscle. Actually the
activation of AMPK stimulated muscle glucose transport (Huang
and Czech, 2007). Once the glucose was taken up, it could be
stored as glycogen or metabolized by glycolysis to generate ATP.
Numerous studies showed that activation of AMPK was both
involved in the pathway of glycolysis and glycogen synthesis
(Barré et al., 2007; Viollet et al., 2009). The metabolic switch after
AMPK activation was mainly dependent on the energy status
of the cells. Here, we demonstrated that ORM/CCR5-triggered
AMPK could induce glycogen storage in skeletal muscle, which is
critical for the effect of ORM in the exercise performance.
Long-term/chronic activation of AMPK increases glycogen
storage in skeletal (Holmes et al., 1999; Ojuka et al., 2000)
and cardiac (Luptak et al., 2007) muscles. Glycogen synthase,
catalyzing the addition of glucose residues to the non-reducing
end of a nascent glycogen chain, has been considered as the key
rate limiting enzyme for glycogen synthesis in all organs (Roach
et al., 1998). Its activity was regulated through phosphorylation
at multiple sites (Bollen et al., 1998). Phosphorylation tends
to inactivate glycogen synthase and dephosphorylation results
in its subsequent activation. Roger W et al recently found
that AMPK activation causes an elevated glucose transport and
accumulation of intracellular G6P, which leads to allosteric
activation of GS resulting in a net increase in GS activity
and excess glycogen storage in muscle cells (Hunter et al.,
2011). Our present results showed that ORM/CCR5-triggered
AMPK could increase the expression of total GS, decrease
the ratio of phosphorylated GS in total GS, increase muscle
GS activity, and be responsible for the effect of glycogen
storage of ORM. It is worth noting that basal glycogen content
was reduced in mice deficient in AMPKα2, while basal GS
activity was not changed in mice deficient in AMPKα2 or
CCR5, indicating an alternative pathway may be involved in
the regulation of glycogen storage in embryo development.
Moreover, a recent study further indicated that AMPK controls
exercise endurance through increasing mitochondrial oxidative
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capacity and substrate utilization (Lantier et al., 2014). It is
conceivable that the change of glucose transporter andGS activity
are secondary to the enhancement of mitochondrial function,
which should be further explored.
In summary, our present data showed that ORM promotes
muscle glycogen accumulation via CCR5-AMPK-glycogen
synthase pathway, representing a new energy homeostasis
regulatory mechanism when body meets stress, and also a
possible target acting as a potential antidiabetic drug due to its
glycogen storage effect. Considering that ORM can increase
glucose uptake in 3T3-L1 adipocytes (Lee et al., 2010) and
regulate whole body energy homeostasis (Sun et al., 2016), it is
conceivable that when systemic administration of ORM, these
effects may also influence the direct role of ORM in muscle
endurance, and the potential cross talk between them should also
be explored in the future.
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